Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calcification tissue, an anti-calcification preparation that transforms xenograft tissue into durable bioscaffolds that are used to mimic human tissue for surgical repair in multiple settings, including aortic valve replacement; and ComASUR delivery system, a physician-developed balloon expandable delivery system that contains a reinforced steerable catheter for a precise deflection through the heart anatomy in a controlled manner to avoid damage to the aorta. Anteris Technologies Global Corp. is based in Toowong, Australia. Show more
Location: Toowong Tower, Toowong, QLD, 4066, Australia | Website: https://anteristech.com | Industry: Medical Instruments & Supplies | Sector: Healthcare
Market Cap
158.6M
52 Wk Range
$2.34 - $8.79
Previous Close
$3.85
Open
$3.86
Volume
51,353
Day Range
$3.86 - $4.04
Enterprise Value
151.8M
Cash
9.119M
Avg Qtr Burn
-19.38M
Insider Ownership
0.19%
Institutional Own.
61.12%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
